Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
- Published In:
- Journal of neuroendocrinology, 37(3), e13355 (2025)
- Database ID:
- RPEP-10342
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10342APA
Chan, Dennis S; Kanagaratnam, Aran L; Pavlakis, Nick; Chan, David L. (2025). Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.. Journal of neuroendocrinology, 37(3), e13355. https://doi.org/10.1111/jne.13355
MLA
Chan, Dennis S, et al. "Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.." Journal of neuroendocrinology, 2025. https://doi.org/10.1111/jne.13355
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor chemoradionuclide therapy for neuroendocrin..." RPEP-10342. Retrieved from https://rethinkpeptides.com/research/chan-2025-peptide-receptor-chemoradionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.